Back

Cue Biopharma reports Phase 2 CUE-221 results from 145 CSU patients

Verifying
  • Cue Biopharma announced positive topline Phase 2 results for CUE-221 in chronic spontaneous urticaria.
  • The China trial enrolled 145 participants and tested three CUE-221 doses against placebo and omalizumab.
  • Cue Biopharma plans Phase 2b/3 CSU and Phase 2 food-allergy studies.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.